星空体育官方入口网站网址大全-登录入口官网

#EASL2024#

0篇内容 | 217人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2216308, encodeId=228c2216308cd, content=<a href='/topic/show?id=488344261c3' target=_blank style='color:#2F92EE;'>#失代偿期肝硬化#</a> <a href='/topic/show?id=40a21153043b' target=_blank style='color:#2F92EE;'>#EASL2024#</a>, objectTitle=失代偿期肝硬化患者的再代偿——EASL 2024带来的证据与希望, objectType=article, longId=834910, objectId=186c8349100d, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240624/1719201193789_92910.png, objectUrl=/article/show_article.do?id=186c8349100d, replyNumber=0, likeNumber=13, createdTime=2024-07-22, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=186c8349100d, moduleTitle=失代偿期肝硬化患者的再代偿——EASL 2024带来的证据与希望, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=186c8349100d)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2213312, encodeId=e772221331252, content=<a href='/topic/show?id=315a5342562' target=_blank style='color:#2F92EE;'>#慢乙肝#</a> <a href='/topic/show?id=412f62143da' target=_blank style='color:#2F92EE;'>#核苷#</a> <a href='/topic/show?id=40a21153043b' target=_blank style='color:#2F92EE;'>#EASL2024#</a> <a href='/topic/show?id=f8a111624364' target=_blank style='color:#2F92EE;'>#ALT急性升高#</a>, objectTitle=【EASL2024速递】全球多中心研究：核苷停药后近60%的慢乙肝患者出现ALT急性升高, objectType=article, longId=829507, objectId=037982950e5b, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240704/1720103957892_1608702.png, objectUrl=/article/show_article.do?id=037982950e5b, replyNumber=0, likeNumber=40, createdTime=2024-07-04, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=037982950e5b, moduleTitle=【EASL2024速递】全球多中心研究：核苷停药后近60%的慢乙肝患者出现ALT急性升高, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=037982950e5b)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2212928, encodeId=80472212928cd, content=<a href='/topic/show?id=9d23554e95a' target=_blank style='color:#2F92EE;'>#抗病毒治疗#</a> <a href='/topic/show?id=315a5342562' target=_blank style='color:#2F92EE;'>#慢乙肝#</a> <a href='/topic/show?id=40a21153043b' target=_blank style='color:#2F92EE;'>#EASL2024#</a>, objectTitle=【EASL2024速递】韩国Young-Suk Lim教授团队：较高病毒载量的不确定期患者及时启动抗病毒治疗更具成本效益, objectType=article, longId=829351, objectId=060b82935139, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240702/1719906386334_1608702.jpg, objectUrl=/article/show_article.do?id=060b82935139, replyNumber=0, likeNumber=26, createdTime=2024-07-03, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=060b82935139, moduleTitle=【EASL2024速递】韩国Young-Suk Lim教授团队：较高病毒载量的不确定期患者及时启动抗病毒治疗更具成本效益, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=060b82935139)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2212293, encodeId=80ca2212293d5, content=<a href='/topic/show?id=cf292341925' target=_blank style='color:#2F92EE;'>#乙肝#</a> <a href='/topic/show?id=40a21153043b' target=_blank style='color:#2F92EE;'>#EASL2024#</a> <a href='/topic/show?id=f1d1116025fe' target=_blank style='color:#2F92EE;'>#HBsAg特异性B细胞#</a>, objectTitle=【EASL2024速递】聚焦慢乙肝患者HBsAg特异性B细胞, objectType=article, longId=829227, objectId=2e5782922e32, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240629/1719624789928_5579292.jpg, objectUrl=/article/show_article.do?id=2e5782922e32, replyNumber=0, likeNumber=31, createdTime=2024-06-29, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=2e5782922e32, moduleTitle=【EASL2024速递】聚焦慢乙肝患者HBsAg特异性B细胞, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=2e5782922e32)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2212222, encodeId=7e772212222cd, content=<a href='/topic/show?id=5df56936690' target=_blank style='color:#2F92EE;'>#生物标志物#</a> <a href='/topic/show?id=45901948312' target=_blank style='color:#2F92EE;'>#丁肝#</a> <a href='/topic/show?id=40a21153043b' target=_blank style='color:#2F92EE;'>#EASL2024#</a>, objectTitle=【EASL2024速递】多中心研究：大、中表面蛋白是丁肝患者治疗应答的潜在生物标志物, objectType=article, longId=829079, objectId=fb9f8290e964, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240628/1719539526128_5579292.png, objectUrl=/article/show_article.do?id=fb9f8290e964, replyNumber=0, likeNumber=42, createdTime=2024-06-28, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=fb9f8290e964, moduleTitle=【EASL2024速递】多中心研究：大、中表面蛋白是丁肝患者治疗应答的潜在生物标志物, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=fb9f8290e964)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2212245, encodeId=f80d221224551, content=<a href='/topic/show?id=59ad2914473' target=_blank style='color:#2F92EE;'>#免疫耐受期#</a> <a href='/topic/show?id=40a21153043b' target=_blank style='color:#2F92EE;'>#EASL2024#</a> <a href='/topic/show?id=f17f116004a9' target=_blank style='color:#2F92EE;'>#HBV相关肝脏疾病#</a>, objectTitle=【EASL2024速递】荟萃分析：免疫耐受期和灰区患者有较高的HBV相关肝脏疾病发生风险, objectType=article, longId=828161, objectId=571182816126, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240619/1718795464407_5579292.jpg, objectUrl=/article/show_article.do?id=571182816126, replyNumber=0, likeNumber=37, createdTime=2024-06-28, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=571182816126, moduleTitle=【EASL2024速递】荟萃分析：免疫耐受期和灰区患者有较高的HBV相关肝脏疾病发生风险, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=571182816126)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2212249, encodeId=ae0b221224966, content=<a href='/topic/show?id=cf292341925' target=_blank style='color:#2F92EE;'>#乙肝#</a> <a href='/topic/show?id=40a21153043b' target=_blank style='color:#2F92EE;'>#EASL2024#</a> <a href='/topic/show?id=5fbb11600e0a' target=_blank style='color:#2F92EE;'>#AB-729#</a>, objectTitle=【EASL2024速递】乙肝新药AB-729联合治疗的研究进展, objectType=article, longId=828417, objectId=06e282841eba, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240621/1718956004306_5579292.png, objectUrl=/article/show_article.do?id=06e282841eba, replyNumber=0, likeNumber=88, createdTime=2024-06-28, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=06e282841eba, moduleTitle=【EASL2024速递】乙肝新药AB-729联合治疗的研究进展, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=06e282841eba)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2212256, encodeId=765c22122562c, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a> <a href='/topic/show?id=2a3f2343353' target=_blank style='color:#2F92EE;'>#乙肝新药#</a> <a href='/topic/show?id=458210328bf' target=_blank style='color:#2F92EE;'>#JNJ-3989#</a> <a href='/topic/show?id=40a21153043b' target=_blank style='color:#2F92EE;'>#EASL2024#</a>, objectTitle=【EASL2024速递】乙肝新药JNJ-3989研究进展汇总, objectType=article, longId=828911, objectId=e1d1828911a8, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240625/1719326958545_5579292.jpg, objectUrl=/article/show_article.do?id=e1d1828911a8, replyNumber=0, likeNumber=30, createdTime=2024-06-28, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=e1d1828911a8, moduleTitle=【EASL2024速递】乙肝新药JNJ-3989研究进展汇总, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=e1d1828911a8)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2209535, encodeId=75742209535ed, content=<a href='/topic/show?id=aa791400831' target=_blank style='color:#2F92EE;'>#pegIFNα#</a> <a href='/topic/show?id=315a5342562' target=_blank style='color:#2F92EE;'>#慢乙肝#</a> <a href='/topic/show?id=40a21153043b' target=_blank style='color:#2F92EE;'>#EASL2024#</a> <a href='/topic/show?id=65d511543e88' target=_blank style='color:#2F92EE;'>#抗-HBc水平#</a>, objectTitle=【EASL2024速递】新证据：基线较高的抗-HBc水平与更好的PegIFNα治疗疗效相关, objectType=article, longId=828021, objectId=612882802122, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240612/1718167913254_1608702.jpg, objectUrl=/article/show_article.do?id=612882802122, replyNumber=0, likeNumber=25, createdTime=2024-06-12, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=612882802122, moduleTitle=【EASL2024速递】新证据：基线较高的抗-HBc水平与更好的PegIFNα治疗疗效相关, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=612882802122)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2208889, encodeId=555e2208889a7, content=<a href='/topic/show?id=4f77e665253' target=_blank style='color:#2F92EE;'><a href='/topic/show?id=2ad5104395dc' target=_blank style='color:#2F92EE;'>#糖尿病#</a></a> <a href='/topic/show?id=3ed881343fa' target=_blank style='color:#2F92EE;'>#肝纤维化#</a> <a href='/topic/show?id=315a5342562' target=_blank style='color:#2F92EE;'>#慢乙肝#</a> <a href='/topic/show?id=40a21153043b' target=_blank style='color:#2F92EE;'>#EASL2024#</a>, objectTitle=【EASL2024速递】糖尿病与慢乙肝患者肝纤维化进展风险显著相关, objectType=article, longId=827643, objectId=45a182e64382, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240607/1717775297944_5579292.jpg, objectUrl=/article/show_article.do?id=45a182e64382, replyNumber=0, likeNumber=74, createdTime=2024-06-07, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=45a182e64382, moduleTitle=【EASL2024速递】糖尿病与慢乙肝患者肝纤维化进展风险显著相关, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=45a182e64382)], followStatus=false, userIsMember=false, type=null, lengthMark=0)] 梅斯管理员

糖尿病肝纤维化慢乙肝 EASL2024

2024-06-07发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#失代偿期肝硬化# #EASL2024#

失代偿期肝硬化患者的再代偿——EASL 2024带来的证据与希望

2024-07-22发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#慢乙肝# #核苷# #EASL2024# #ALT急性升高#

【EASL2024速递】全球多中心研究：核苷停药后近60%的慢乙肝患者出现ALT急性升高

2024-07-04发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#抗病毒治疗# #慢乙肝# #EASL2024#

【EASL2024速递】韩国Young-Suk Lim教授团队：较高病毒载量的不确定期患者及时启动抗病毒治疗更具成本效益

2024-07-03发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#乙肝# #EASL2024# #HBsAg特异性B细胞#

【EASL2024速递】聚焦慢乙肝患者HBsAg特异性B细胞

2024-06-29发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#生物标志物# #丁肝# #EASL2024#

【EASL2024速递】多中心研究：大、中表面蛋白是丁肝患者治疗应答的潜在生物标志物

2024-06-28发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#免疫耐受期# #EASL2024# #HBV相关肝脏疾病#

【EASL2024速递】荟萃分析：免疫耐受期和灰区患者有较高的HBV相关肝脏疾病发生风险

2024-06-28发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#乙肝# #EASL2024# #AB-729#

【EASL2024速递】乙肝新药AB-729联合治疗的研究进展

2024-06-28发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#联合治疗# #乙肝新药# #JNJ-3989# #EASL2024#

【EASL2024速递】乙肝新药JNJ-3989研究进展汇总

2024-06-28发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#pegIFNα# #慢乙肝# #EASL2024# #抗-HBc水平#

【EASL2024速递】新证据：基线较高的抗-HBc水平与更好的PegIFNα治疗疗效相关

2024-06-12发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#糖尿病# #肝纤维化# #慢乙肝# #EASL2024#

【EASL2024速递】糖尿病与慢乙肝患者肝纤维化进展风险显著相关

2024-06-07发表于上海

科室
- - 订阅+
  - 更多科室
工具
服务